Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Trends in clinical trials of dengue vaccine.

Marimuthu P, Ravinder JR.

Perspect Clin Res. 2016 Oct-Dec;7(4):161-164. Review.

2.

Zika Virus: Immunity and Vaccine Development.

Pierson TC, Graham BS.

Cell. 2016 Oct 20;167(3):625-631. doi: 10.1016/j.cell.2016.09.020. Review.

PMID:
27693357
3.

Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach.

Zubieta-Zavala A, Salinas-Escudero G, Ramírez-Chávez A, García-Valladares L, López-Cervantes M, López Yescas JG, Durán-Arenas L.

PLoS Negl Trop Dis. 2016 Aug 8;10(8):e0004897. doi: 10.1371/journal.pntd.0004897. Erratum in: PLoS Negl Trop Dis. 2016 Nov 1;10 (11):e0005119.

4.

A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine Candidates.

Govindarajan D, Guan L, Meschino S, Fridman A, Bagchi A, Pak I, ter Meulen J, Casimiro DR, Bett AJ.

PLoS One. 2016 Mar 23;11(3):e0152209. doi: 10.1371/journal.pone.0152209.

5.

An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH.

Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268.

6.

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL, Luy BE, Arguello J, Beatty ME, Santangelo J, Gordon GS, Huang CY, Stinchcomb DT.

Lancet Infect Dis. 2014 Sep;14(9):830-8. doi: 10.1016/S1473-3099(14)70811-4.

7.

Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Althouse BM, Durbin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA.

Virology. 2014 Mar;452-453:237-46. doi: 10.1016/j.virol.2014.01.015. Review.

8.

Efficient generation of human iPSCs by a synthetic self-replicative RNA.

Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, Muotri AR, Chi NC, Fu XD, Yu BD, Dowdy SF.

Cell Stem Cell. 2013 Aug 1;13(2):246-54. doi: 10.1016/j.stem.2013.06.001.

9.

Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge.

Henriques HR, Rampazo EV, Gonçalves AJ, Vicentin EC, Amorim JH, Panatieri RH, Amorim KN, Yamamoto MM, Ferreira LC, Alves AM, Boscardin SB.

PLoS Negl Trop Dis. 2013 Jul 18;7(7):e2330. doi: 10.1371/journal.pntd.0002330.

10.

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.

Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, Li Ng J, Yun Toh X, Archuleta S, Wilder-Smith A, Shek LP, Wartel-Tram A, Bouckenooghe A, Lang J, Crevat D, Caillet C, Guy B.

Hum Vaccin Immunother. 2013 Nov;9(11):2317-25.

11.

HLA-B∗44 Is Associated with Dengue Severity Caused by DENV-3 in a Brazilian Population.

Xavier Eurico de Alencar L, de Mendonça Braga-Neto U, José Moura do Nascimento E, Tenório Cordeiro M, Maria Silva A, Alexandre Antunes de Brito C, da Silva Mda P, Gil LH, Montenegro SM, Marques ET Jr.

J Trop Med. 2013;2013:648475. doi: 10.1155/2013/648475.

12.

Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E.

PLoS Negl Trop Dis. 2013 Jun 13;7(6):e2274. doi: 10.1371/journal.pntd.0002274.

13.

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13.

14.

Reduced risk of disease during postsecondary dengue virus infections.

Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST.

J Infect Dis. 2013 Sep;208(6):1026-33. doi: 10.1093/infdis/jit273.

15.

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.

Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD.

Vaccine. 2013 Jul 18;31(33):3347-52. doi: 10.1016/j.vaccine.2013.05.075.

16.

Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N.

Infect Genet Evol. 2013 Oct;19:292-311. doi: 10.1016/j.meegid.2013.03.008. Review.

17.

Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination.

Coudeville L, Garnett GP.

PLoS One. 2012;7(12):e51244. doi: 10.1371/journal.pone.0051244.

18.

Sculpting humoral immunity through dengue vaccination to enhance protective immunity.

Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ.

Front Immunol. 2012 Nov 8;3:334. doi: 10.3389/fimmu.2012.00334.

19.

Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S.

J Virol. 2013 Jan;87(1):52-66. doi: 10.1128/JVI.02273-12.

20.

Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis.

Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J.

BMC Infect Dis. 2012 Sep 28;12:233. doi: 10.1186/1471-2334-12-233. Review.

Items per page

Supplemental Content

Support Center